drugset / Trial / NCT06654440
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
Timeline
- Start
- 2024-11-15
- Primary completion
- 2025-08-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-A2102 | Other / unclassified | — | — |